Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology - PubMed (original) (raw)
Guideline
Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology
J M Miyasaki et al. Neurology. 2002.
Abstract
In 1993, the last AAN Practice Parameter on medical treatment of Parkinson's disease (PD) concluded that levodopa was the most effective drug for management of this disorder. Since then, a number of new compounds including non-ergot dopamine agonists (DA) and sustained-release levodopa have been released and studied. Thus, the issue of treatment in de novo PD patients warrants reexamination. Specific questions include: 1) does selegiline offer neuroprotection; 2) what is the best agent with which to initiate symptomatic treatment in de novo PD; and 3) is there a benefit of sustained release levodopa over immediate-release levodopa? Using evidence-based principles, a literature review using MEDLINE, EMBASE, and the Cochrane Library was performed to identify all human trials in de novo PD between 1966 and 1999. Only articles that fulfilled class I or class II evidence were included. Based on this review, the authors conclude: 1) Selegiline has very mild symptomatic benefit (level A, class II evidence) with no evidence for neuroprotective benefit (level U, class II evidence). 2) For PD patients requiring initiation of symptomatic therapy, either levodopa or a DA can be used (level A, class I and class II evidence). Levodopa provides superior motor benefit but is associated with a higher risk of dyskinesia. 3) No evidence was found that initiating treatment with sustained-release levodopa provides an advantage over immediate-release levodopa (level B, class II evidence).
Comment in
- Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review.
Inzelberg R, Nisipeanu P, Schechtman E. Inzelberg R, et al. Neurology. 2002 Oct 22;59(8):1292; author reply 1292. doi: 10.1212/wnl.59.8.1292. Neurology. 2002. PMID: 12391377 No abstract available.
Similar articles
- Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.
Pahwa R, Factor SA, Lyons KE, Ondo WG, Gronseth G, Bronte-Stewart H, Hallett M, Miyasaki J, Stevens J, Weiner WJ; Quality Standards Subcommittee of the American Academy of Neurology. Pahwa R, et al. Neurology. 2006 Apr 11;66(7):983-95. doi: 10.1212/01.wnl.0000215250.82576.87. Neurology. 2006. PMID: 16606909 Review. - Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease.
Caslake R, Macleod A, Ives N, Stowe R, Counsell C. Caslake R, et al. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD006661. doi: 10.1002/14651858.CD006661.pub2. Cochrane Database Syst Rev. 2009. PMID: 19821381 Review. - Early Parkinson's disease: what is the best approach to treatment.
Hristova AH, Koller WC. Hristova AH, et al. Drugs Aging. 2000 Sep;17(3):165-81. doi: 10.2165/00002512-200017030-00002. Drugs Aging. 2000. PMID: 11043817 Review. - Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
Jankovic J, Stacy M. Jankovic J, et al. CNS Drugs. 2007;21(8):677-92. doi: 10.2165/00023210-200721080-00005. CNS Drugs. 2007. PMID: 17630819 Review. - Practice Parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.
Suchowersky O, Gronseth G, Perlmutter J, Reich S, Zesiewicz T, Weiner WJ; Quality Standards Subcommittee of the American Academy of Neurology. Suchowersky O, et al. Neurology. 2006 Apr 11;66(7):976-82. doi: 10.1212/01.wnl.0000206363.57955.1b. Neurology. 2006. PMID: 16606908
Cited by
- Racial Disparities in Low-Value Care in the Last Year of Life for Medicare Beneficiaries With Neurodegenerative Disease.
Goetz ME, Ford CB, Greiner MA, Clark A, Johnson KG, Kaufman BG, Mantri S, Xian Y, O'Brien RJ, O'Brien EC, Lusk JB. Goetz ME, et al. Neurol Clin Pract. 2024 Apr;14(2):e200273. doi: 10.1212/CPJ.0000000000200273. Epub 2024 Mar 15. Neurol Clin Pract. 2024. PMID: 38524836 - Keystroke Biometrics as a Tool for the Early Diagnosis and Clinical Assessment of Parkinson's Disease.
Liu WM, Yeh CL, Chen PW, Lin CW, Liu AB. Liu WM, et al. Diagnostics (Basel). 2023 Sep 26;13(19):3061. doi: 10.3390/diagnostics13193061. Diagnostics (Basel). 2023. PMID: 37835803 Free PMC article. - Comparative motor effectiveness of non-invasive brain stimulation techniques in patients with Parkinson's disease: A network meta-analysis.
Liu X, Li L, Liu Y. Liu X, et al. Medicine (Baltimore). 2023 Sep 29;102(39):e34960. doi: 10.1097/MD.0000000000034960. Medicine (Baltimore). 2023. PMID: 37773851 Free PMC article. - Clinical Use of On-Demand Therapies for Patients with Parkinson's Disease and OFF Periods.
Pahwa R, Pagan FL, Kremens DE, Saint-Hilaire M. Pahwa R, et al. Neurol Ther. 2023 Aug;12(4):1033-1049. doi: 10.1007/s40120-023-00486-5. Epub 2023 May 23. Neurol Ther. 2023. PMID: 37221354 Free PMC article. Review. - Safety and Effectiveness of Rasagiline in Chinese Patients with Parkinson's Disease: A Prospective, Multicenter, Non-interventional Post-marketing Study.
Su W, Liang Z, Mao W, Shao M, Hu X, Wu Y, Wei W, Liu Z, Zhang K, Tang B, Cao S, Song Z, Chen H. Su W, et al. Drug Saf. 2023 Jul;46(7):637-646. doi: 10.1007/s40264-023-01288-2. Epub 2023 May 17. Drug Saf. 2023. PMID: 37195560 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical